Zobrazeno 1 - 10
of 86
pro vyhledávání: '"G. Nuciforo"'
Autor:
Tom Venken, Ian S. Miller, Ingrid Arijs, Valentina Thomas, Ana Barat, Johannes Betge, Tianzuo Zhan, Timo Gaiser, Matthias P. Ebert, Alice C. O’Farrell, Jochen Prehn, Rut Klinger, Darran P. O’Connor, Brian Moulton, Verena Murphy, Garazi Serna, Paolo G. Nuciforo, Ray McDermott, Brian Bird, Gregory Leonard, Liam Grogan, Anne Horgan, Nadine Schulte, Markus Moehler, Diether Lambrechts, Annette T. Byrne
Publikováno v:
npj Genomic Medicine, Vol 9, Iss 1, Pp 1-10 (2024)
Abstract To predict outcome to combination bevacizumab (BVZ) therapy, we employed cell-free DNA (cfDNA) to determine chromosomal instability (CIN), nucleosome footprints (NF) and methylation profiles in metastatic colorectal cancer (mCRC) patients. L
Externí odkaz:
https://doaj.org/article/7492becf8fc3468584cbff1ca25b4e7f
Autor:
Tian V. Tian, Teresa Macarulla, Sandra Peiró, Josep Tabernero, Joaquín Arribas, Violeta Serra, Marta Melé, Ana Vivancos, Paolo G. Nuciforo, Josep M. Miquel, Óscar J. Pozo, Francis J. Giles, Noemí Haro, Cristina Bernadó-Morales, Enrique J. Arenas, Marta Escorihuela, Carmen Escudero-Iriarte, Carles Fabregat-Franco, Florian Castet, Mariana Yáñez-Bartolomé, Jessica Querol, Joan Frigola, Cindy Neuzillet, Anthony Turpin, Maria Vila-Casadesús, Cristina Molina, Alba Llop-Guevara, Núria Lupión-Garcia, Winona Oliveros, Helena Verdaguer, Queralt Serra-Camprubí
Genomic rearrangements resulting in FGFR2 fusions. (A) Genomic rearrangements resulting in FGFR2 fusion identified in CCA_PDX and the corresponding biopsy samples. Fusion partner genes, their accession number, breakpoints, and predicted chimeric prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::107e366b8b3d02a05576d36fb83265fb
https://doi.org/10.1158/1078-0432.22489007
https://doi.org/10.1158/1078-0432.22489007
Autor:
Tian V. Tian, Teresa Macarulla, Sandra Peiró, Josep Tabernero, Joaquín Arribas, Violeta Serra, Marta Melé, Ana Vivancos, Paolo G. Nuciforo, Josep M. Miquel, Óscar J. Pozo, Francis J. Giles, Noemí Haro, Cristina Bernadó-Morales, Enrique J. Arenas, Marta Escorihuela, Carmen Escudero-Iriarte, Carles Fabregat-Franco, Florian Castet, Mariana Yáñez-Bartolomé, Jessica Querol, Joan Frigola, Cindy Neuzillet, Anthony Turpin, Maria Vila-Casadesús, Cristina Molina, Alba Llop-Guevara, Núria Lupión-Garcia, Winona Oliveros, Helena Verdaguer, Queralt Serra-Camprubí
Information of patients underwent the biopsy procedures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c01603d143aabc99513a7d81963a854
https://doi.org/10.1158/1078-0432.22488986.v1
https://doi.org/10.1158/1078-0432.22488986.v1
Autor:
Tian V. Tian, Teresa Macarulla, Sandra Peiró, Josep Tabernero, Joaquín Arribas, Violeta Serra, Marta Melé, Ana Vivancos, Paolo G. Nuciforo, Josep M. Miquel, Óscar J. Pozo, Francis J. Giles, Noemí Haro, Cristina Bernadó-Morales, Enrique J. Arenas, Marta Escorihuela, Carmen Escudero-Iriarte, Carles Fabregat-Franco, Florian Castet, Mariana Yáñez-Bartolomé, Jessica Querol, Joan Frigola, Cindy Neuzillet, Anthony Turpin, Maria Vila-Casadesús, Cristina Molina, Alba Llop-Guevara, Núria Lupión-Garcia, Winona Oliveros, Helena Verdaguer, Queralt Serra-Camprubí
Purpose:Cholangiocarcinoma (CCA) is usually diagnosed at advanced stages, with limited therapeutic options. Preclinical models focused on unresectable metastatic CCA are necessary to develop rational treatments. Pathogenic mutations in IDH1/2, ARID1A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ffad5473b6ac95e115576bc8c4bb844
https://doi.org/10.1158/1078-0432.c.6532853.v1
https://doi.org/10.1158/1078-0432.c.6532853.v1
Autor:
Steven J. Isakoff, Mafalda Oliveira, Emanuel F. Petricoin, Matthew J. Wongchenko, Patricia Villagrasa, Eva M. Ciruelos, Debra A. Pratt, Begoña Bermejo, Miguel J. Gil-Gil, José Luis Passos-Coelho, Jay Andersen, Isabel Calvo, Paolo G. Nuciforo, Cristina Saura, Rosa I. Gallagher, Malgorzata Nowicka, Julia Wulfkuhle, Zhen Shi
Purpose:Despite extensive genomic and transcriptomic profiling, it remains unknown how signaling pathways are differentially activated and how tumors are differentially sensitized to certain perturbations. Here, we aim to characterize AKT signaling a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e2eca09880115d1cf4d33de9bed5dff
https://doi.org/10.1158/1078-0432.c.6531054.v1
https://doi.org/10.1158/1078-0432.c.6531054.v1
Autor:
Steven J. Isakoff, Mafalda Oliveira, Emanuel F. Petricoin, Matthew J. Wongchenko, Patricia Villagrasa, Eva M. Ciruelos, Debra A. Pratt, Begoña Bermejo, Miguel J. Gil-Gil, José Luis Passos-Coelho, Jay Andersen, Isabel Calvo, Paolo G. Nuciforo, Cristina Saura, Rosa I. Gallagher, Malgorzata Nowicka, Julia Wulfkuhle, Zhen Shi
Supplementary Table from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41492d989e0ac9835fc4814324324071
https://doi.org/10.1158/1078-0432.22483008
https://doi.org/10.1158/1078-0432.22483008
Autor:
Steven J. Isakoff, Mafalda Oliveira, Emanuel F. Petricoin, Matthew J. Wongchenko, Patricia Villagrasa, Eva M. Ciruelos, Debra A. Pratt, Begoña Bermejo, Miguel J. Gil-Gil, José Luis Passos-Coelho, Jay Andersen, Isabel Calvo, Paolo G. Nuciforo, Cristina Saura, Rosa I. Gallagher, Malgorzata Nowicka, Julia Wulfkuhle, Zhen Shi
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1612c3312664d4b7c8c15ace62e3e525
https://doi.org/10.1158/1078-0432.22483038.v1
https://doi.org/10.1158/1078-0432.22483038.v1
Autor:
Ugo Cavallaro, Paolo G. Nuciforo, Andrew K. Godwin, Meenhard Herlyn, Jinsong Liu, Giuseppe Viale, Chiara Casadio, Giovanni Goisis, Roberta Fasani, Nicoletta Colombo, Marco Bianchi, Silvia Zecchini
Epithelial ovarian carcinoma (EOC) arises from the ovarian surface epithelium (OSE), a monolayer of poorly differentiated epithelial cells that lines the ovary. The molecular mechanisms underlying EOC invasion into the surrounding stroma and dissemin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b67172e5c8d40a0e57c82ef8c84ceb4
https://doi.org/10.1158/0008-5472.c.6497690
https://doi.org/10.1158/0008-5472.c.6497690
Autor:
Ugo Cavallaro, Paolo G. Nuciforo, Andrew K. Godwin, Meenhard Herlyn, Jinsong Liu, Giuseppe Viale, Chiara Casadio, Giovanni Goisis, Roberta Fasani, Nicoletta Colombo, Marco Bianchi, Silvia Zecchini
Supplementary Methods, Tables 1-2, Figures S1-S8 from The Differential Role of L1 in Ovarian Carcinoma and Normal Ovarian Surface Epithelium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532bcd431b3382645e187e562c67a0d2
https://doi.org/10.1158/0008-5472.22375049
https://doi.org/10.1158/0008-5472.22375049
Autor:
Queralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros, Núria Lupión-Garcia, Alba Llop-Guevara, Cristina Molina, Maria Vila-Casadesús, Anthony Turpin, Cindy Neuzillet, Joan Frigola, Jessica Querol, Mariana Yáñez-Bartolomé, Florian Castet, Carles Fabregat-Franco, Carmen Escudero-Iriarte, Marta Escorihuela, Enrique J. Arenas, Cristina Bernadó-Morales, Noemí Haro, Francis J. Giles, Óscar J. Pozo, Josep M. Miquel, Paolo G. Nuciforo, Ana Vivancos, Marta Melé, Violeta Serra, Joaquín Arribas, Josep Tabernero, Sandra Peiró, Teresa Macarulla, Tian V. Tian
Publikováno v:
Scientia
Cholangiocarcinoma (CCA) is usually diagnosed at advanced stages, with limited therapeutic options. Preclinical models focused on unresectable metastatic CCA are necessary to develop rational treatments. Pathogenic mutations in IDH1/2, ARID1A/B, BAP1